News Lilly licenses Hanmi GLP-2 drug in $1.26bn deal Eli Lilly's relentless pipeline-building drive has continued with a licensing deal for Hanmi's sonefpeglutide, in phase 2 for short bowel syndrome.
News Remedy Meds buys telehealth rival in $500m marriage Telehealth startup Remedy Meds has expanded its position in the US market at a stroke with a $500m-plus deal to buy Thirty Madison.
News Positive phase 3 results for Zealand Pharma's glepaglutide Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.